stockrow
Friday 6 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL Healthcare Biotechnology
- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.72
1.70
+8.49%
Follow REPL
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
7.11 | 5.23 | 4.79 | 5.60 |
+8 more quarters Free account |
Net Debt/EBITDA |
3.43 | 1.34 | 2.25 | 2.74 | |
Debt/Assets |
32.42% | 41.91% | 31.65% | 20.91% | |
Debt/Equity |
0.59 | 1.00 | 0.63 | 0.33 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 1.09 | 0.77 | 0.93 | |
Capex/Depreciation |
0.00 | 0.00 | (0.01) | 0.15 | |
Interest Coverage |
(18.61) | (22.11) | (25.49) | (36.30) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.45) | (0.78) | (0.61) | (0.72) | |
Cash per Share |
2.93 | 2.02 | 2.90 | 2.92 | |
Shareholders Equity per Share |
1.95 | 1.09 | 1.79 | 2.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.95 | 1.09 | 1.79 | 2.28 | |
Free Cash Flow |
(47.70) | (75.73) | (56.17) | (66.09) | |
Working Capital |
278.48 | 162.40 | 220.89 | 230.27 | |
Capital Expenditures |
0.00 | (0.01) | 0.00 | (0.13) | |
Net Current Asset Value |
154.87 | 54.01 | 112.89 | 157.30 | |
| Other line items | |||||
Quick Ratio |
6.76 | 5.09 | 4.65 | 5.43 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.78) | (0.61) | (0.72) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | 2.67 | 3.01 | |
Average Payables |
6.18 | 9.87 | 9.57 | 6.42 | |
Average Assets |
381.70 | 360.98 | 441.86 | 468.61 | |
Average Common Equity |
234.06 | 221.18 | 291.00 | 346.46 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026